July 30, 2021 08:49 AM EDT

Biogen launches Phase IV trial to see just how well Aduhelm works in the real world

Nicole DeFeudis

Editor

It could be years before Biogen wraps up its confirmatory trial for its controversial new Alzheimer’s drug Aduhelm (up to nine years, to be precise) …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen launches Phase IV trial to see just how well Aduhelm works in the real world

Nicole DeFeudis

Editor

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Minnesota 340B revenue driven by hospitals and high-priced drugs, first state report says

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Bio­gen launch­es Phase IV tri­al to see just how well Aduhelm works in the re­al world

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

Min­neso­ta 340B rev­enue dri­ven by hos­pi­tals and high-priced drugs, first state re­port says

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Biogen launches Phase IV trial to see just how well Aduhelm works in the real world

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Minnesota 340B revenue driven by hospitals and high-priced drugs, first state report says

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA